Forgot Password?
Return to Course Listing

CME: Who’s on first, and going beyond platinum: strategies for optimizing treatment of extensive-stage small cell lung cancer each step of the way

Activity Description / Statement of Need:

In this online, self-learning activity:

Lung cancer is the leading cause of cancer-related death in the United States, with more than 238,000 new cases diagnosed and over 127,000 deaths annually. The most common type of lung cancer, non–small cell lung cancer (NSCLC), accounts for about 85% of cases and has seen steady declines in mortality over the past several years as improvements have been made in diagnosis, staging, and treatment. In contrast, outcomes for the less prevalent small cell lung cancer (SCLC), which is neuroendocrine in nature and accounts for about 14% of all lung cancer cases, have remained poor in recent years despite improvement in those for NSCLC.

Target Audience:

HCPs including: oncology, pulmonology, and pathology; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with SCLC.

Commercial Support Disclosure: This program is supported by an educational grant from Jazz Pharmaceuticals.

This activity is free of charge.

Release Date: October 31, 2023 -- Expiration Date: October 31, 2024

Faculty: Sandip Patel, MD


Introduction, Disclosures  

SCLC: Pathophysiology and Epidemiology 

  • SCLC epidemiology 
  • Survival outcomes: current and trends 
  • SCLC pathophysiology & biomarkers 
  • Immunotherapeutic targets (PD-1/PD-L1) 
  • Ataxia telangiectasia and rad3-related (ATR) kinase 
  • Other kinases and signaling molecules 

Systemic Therapy in SCLC 

  • Extensive-stage SCLC 
  • Preferred therapy 
  • Consideration of immune checkpoint inhibition in the first-line setting 
  • Assessment of response and monitoring 
  • Relapse considerations 
  • Sensitive- vs. resistant-relapse, relapse before vs. after six months 
  • Second- and later-line treatment options 
  • Additional considerations: performance status, brain metastases 
  • Practical treatment considerations 
  • Need for myeloprotective support 
  • Making sequencing decisions in the absence of level 1 evidence 
  • Best practice: putting it all together 
  • Patient case(s) 

Summary, conclusions, and best practice recap 

Learning Objectives

By the end of the session the participant will be able to:

  • Describe best practices in the identification of extensive-stage SCLC, and apply that information to a patient case.
  • Outline the role of different treatment modalities for extensive-stage SCLC.
  • Formulate a treatment plan for a patient with extensive-stage SCLC.


ACCME Activity #202572903

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-23-041-H01-P. This is an Application (K)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Sandip Patel, MD, Professor, Medical Oncology, UC San Diego, has received financial compensation for consulting from Amgen, AstraZeneca,  BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Rakuten, Signatera, Tempus; and grant research support from: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Jazz Pharmaceuticals. 


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Advanced systemic mastocytosis: from recognition to treatment

Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)

Contemporary approaches and emerging therapies for the management of respiratory syncytial virus in infants and young high-risk children

Taking cover(age): optimizing antimicrobial therapy in the treatment of hospital- and ventilator-acquired bacterial pneumonia